Tag Archives: Death

New York City holds off school closure as U.S. braces for virus-stricken winter

By Gabriella Borter and Anurag Maan

NEW YORK (Reuters) – New York City schools were set to remain open for at least another day despite a rising COVID-19 case count, the mayor said on Tuesday, as surging infections and hospitalizations in the United States from coast to coast prompted new restrictions and predictions of a difficult winter ahead.

New York, home to the nation’s largest school district, reported a 7-day positive COVID-19 test rate of 2.74% on Tuesday – more than double what it was over the summer, but below the 3% threshold that Mayor Bill de Blasio set for keeping schools open.

“Everyone’s been participating in the things that have kept schools safe. Everyone has been wearing their masks … and we need to keep doing that to do our very, very best to keep schools open,” de Blasio told reporters on Tuesday.

“We have some new challenges because of what’s going on around us,” he added.

Beyond New York City, which was the epicenter of the U.S. COVID-19 crisis in the spring, infections have reached unprecedented levels nationwide.

Forty-one U.S. states have reported record increases in COVID-19 cases in November, while 20 have seen a record rise in deaths and 26 reported record hospitalizations, according to a Reuters tally of public health data. Twenty-five states reported test positivity rates above 10% for the week ending on Sunday, Nov. 15. The World Health Organization considers a positivity rate above 5% to be concerning.

The Midwest remains the hardest-hit U.S. region. It reported 444,677 cases in the week ending on Monday, Nov. 16, 36% more than the combined cases of the Northeast and West regions.

The number of coronavirus patients hospitalized in the United States hit a record of 73,140 on Monday. Hospitalizations have increased over 46% in past 14 days, according to a Reuters tally.

New York is among several northeast states that had managed to contain the virus fairly well over the summer after a frightening spring wave, but now has one of the highest week-over-week case increases as of Sunday.

Infections have also jumped in neighboring Connecticut by more than 50% in the last week from the week prior.

“Right now we see the storm clouds coming again,” Connecticut Governor Ned Lamont, a Democrat, told MSNBC in an interview on Tuesday.

Governors of several states and city officials have imposed new restrictions on indoor gatherings in recent days in an attempt to stem the spread of the disease over the winter, with the prospect of a widely available, effective vaccine still months away.

Several have urged citizens to exercise caution around the Thanksgiving holiday and not travel or socialize with extended family for the traditional indoor feast.

“I know this is difficult & frustrating, especially with the holidays right around the corner,” Vermont Governor Phil Scott wrote on Twitter on Tuesday, referring to his ban on multihousehold gatherings. “But it’s necessary & we need your help to get this back under control.”

(Reporting by Gabriella Borter and Anurag Maan; Additional reporting by Susan Heavey and Maria Caspani; Editing by Bill Berkrot)

Moderna vaccine is second to exceed expectations; mutated virus may be more vulnerable to new vaccines

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Vaccine from Moderna is second to exceed expectations in pivotal trial

Moderna Inc’s experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial, the company said on Monday. That followed last week’s news that Pfizer Inc’s vaccine was also more than 90% effective based on initial data. Pending more safety data and regulatory review, the United States could have two vaccines authorized for emergency use in December. Both vaccines employ synthetic messenger RNA (mRNA), which coaxes cells to make certain virus proteins that the immune system sees as a threat and mounts a response against. Moderna’s trial involved 30,000 racially diverse U.S. adults, including people at high risk for severe COVID-19. Only five of the 95 COVID-19 cases in the initial analysis occurred in participants who received the vaccine, while the rest had received a placebo. The vaccine, administered in two shots 28 days apart, also appeared to prevent cases of severe COVID-19. Side effects, largely occurring after the second shot, included muscle aches, fever, headache and redness at the injection site. Moderna’s vaccine does not need ultra-cold storage like Pfizer’s, making it easier to distribute. Moderna expects it to be stable at normal refrigerator temperatures of 2 to 8 degrees Celsius (36 to 48°F) for 30 days and can be stored for up to 6 months at -20C.

Mutated virus may be more vulnerable to new vaccines

The mutated form of the new coronavirus that is now the most common strain worldwide is more infectious but may also be more vulnerable to vaccines under development, new research suggests. In experiments reported on Thursday in Science, researchers saw that the newer strain, which originated in Europe, is more efficient at infecting airway cells and at making copies of itself, although it does not appear to produce more severe illness. The D614G mutation causes a “flap” to open on the tip of a spike on the surface of the virus, improving its ability to break into cells, but also creating a pathway for antibodies in vaccines to enter the virus and disable it, the researchers explained in a statement. New SARS-CoV-2 mutations are continually emerging, “like the recently discovered mink SARS-CoV-2 cluster 5 variant in Denmark that also encodes D614G,” coauthor Ralph Baric of the University of North Carolina School of Medicine said in the statement. “We must continue to track and understand the consequences of these new mutations on disease severity, transmission, host range and vulnerability to vaccine-induced immunity,” he added.

Paper forms pose coronavirus risk for lab staff

When laboratory personnel are processing COVID-19 tests, there is a small risk that the paper forms accompanying the specimens can be contaminated with the new coronavirus, a new report cautions. Researchers at the Birmingham Public Health Laboratory in the UK analyzed randomly selected paper forms and specimen packaging during a period when the team was processing about 700 COVID-19 tests daily. Of the 37 items they tested, one piece of paperwork carried genetic material from the coronavirus. The form had come from a low-risk hospital ward, and the specimen from the patient was negative for the virus, “indicating contamination may be occurring as a result of environmental or healthcare worker contamination,” the researchers wrote on Thursday in the Journal of Hospital Infection. They call for “stringent laboratory practices” – hand hygiene, appropriate personal protective equipment – and “use of electronic test requesting where possible.”

(Reporting by Nancy Lapid, Julie Steenhuysen and Michael Erman; Editing by Bill Berkrot)

U.S. COVID-19 cases cross 11 million as pandemic intensifies

By Roshan Abraham and Seerat Gupta

(Reuters) – The number of coronavirus cases in the United States crossed the 11-million mark on Sunday reaching yet another grim milestone, according to a Reuters tally, as the third wave of COVID-19 infections surged across the country.

Reuters data shows the pace of the pandemic in the United States has quickened, with one million more new cases from just 8 days ago when it hit 10 million, making it the fastest since the pandemic began. This compares with 10 days it took to get from 9 to 10 million and 16 days it took to reach 9 million from 8 million cases.

The United States, hardest-hit by the coronavirus, crossed 10 million COVID-19 cases on November 8 and is reporting over 100,000 daily cases for the past 11 days straight.

The latest 7-day average, shows the United States is reporting more than 144,000 daily cases and 1,120 daily deaths, the highest for any country in the world.

Texas and California have reported the highest number of COVID-19 infections across the United States, together accounting for about 2.1 million cases or about 19% of the total cases since the pandemic began, according to Reuters analysis.

As COVID-19 related hospitalizations continue to rise, crossing 69,000 on Saturday, U.S. President-elect Joe Biden’s top advisers have stressed the need to control the pandemic, warning that local healthcare systems are at a tipping point.

The Midwest remains the hardest-hit region based on the most cases per capita with North Dakota, South Dakota, Wisconsin, Iowa and Nebraska the top five worst-affected U.S. states.

Illinois, which has emerged as the pandemic’s new epicenter in the region as well as across the country, reported a record 15,433 new cases on Friday, the most of any state in a 24-hour period, surpassing the previous all-time high of 15,300 set by Florida in July.

Several states this week re-imposed restrictions to curb the spread of the virus across the nation. North Dakota became the latest state to require that face coverings be worn in public, as it joins 39 other states this month in reporting record daily jumps in new cases.

State governors urged residents to stay home as much as possible, including Nevada Democrat Steve Sisolak, who said late on Friday that he became the fourth governor to become infected with the virus.

The United States accounts for about 20% of more than 54 million global cases and close to 19% of the 1.31 million deaths reported worldwide, according to a Reuters tally.

(Reporting by Roshan Abraham and Seerat Gupta in Bengaluru; editing by Diane Craft)

U.S. CDC reports 242,216 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Friday reported 10,508,864 cases of the novel coronavirus, an increase of 194,610 cases from its previous count, and said that the number of deaths had risen by 1,147 to 242,216.

The CDC reported its tally of cases of the respiratory illness known as COVID-19 as of 4 p.m. ET on Nov. 12, compared with its previous report released a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Aditya Soni)

Measles surging as COVID-19 curbs disrupt vaccinations

By Kate Kelland

LONDON (Reuters) – Measles surged to infect almost 870,000 people across the world in 2019, the worst figures in almost a quarter of a century as vaccination levels fell below critical levels, a report said on Thursday.

Millions of children are at risk of the disease again this year as restrictions imposed to contain the COVID-19 pandemic further disrupt immunization programs, the report co-led by the World Health Organization (WHO) said.

Measles is one of the most contagious known diseases – more so than COVID-19, Ebola, tuberculosis or flu.

More than 207,000 people died of it last year alone, the report found. With immunization coverage below the critical 95% needed for community protection, infections rose in all WHO regions last year to the worst levels since 1996, it said.

“These data send a clear message that we are failing to protect children from measles in every region of the world,” the WHO’s Director-General, Tedros Adhanom Ghebreyesus, said in a statement.

The surge in fatal cases means global measles deaths have risen nearly 50% since 2016.

The report, co-led by the United States Centers for Disease Control and Prevention (CDC), cited a collective failure to fully immunize children on time with two doses of measles vaccine as the main driver of the deadly increases.

Looking ahead to 2020, the report warned that disruptions to vaccination due to the COVID-19 pandemic have crippled efforts to curb measles outbreaks.

As of this month, more than 94 million people were at risk of missing measles vaccinations due to paused immunization campaigns in 26 countries, it said.

“COVID-19 has resulted in dangerous declines in immunization coverage,” Seth Berkley, chief executive of the GAVI global vaccine alliance, said.

He described the “alarming” measles report was “a warning that, with the COVID-19 pandemic occupying health systems across the world, we cannot afford to take our eye off the ball.”

After steady downward progress from 2010 to 2016, measles cases began rising again from 2017. The report said there were a total of 869,770 measles cases, with 207,500 deaths, in 2019.

WHO and the UN children’s fund UNICEF urged governments last week to act now to prevent epidemics of measles, polio and other infectious diseases.

(Reporting by Kate Kelland, editing by Andrew Heavens)

Explainer – Shot in the dark: Early COVID-19 vaccine efficacy explained

By John Miller

ZURICH (Reuters) – This week has seen a flurry of good news from COVID-19 vaccine developers, with Pfizer Inc. and BioNTech SE trumpeting early data indicating their mRNA candidate is more than 90% effective.

A Russian project came out a day later, touting 92% efficacy for the Sputnik V candidate, named after the Soviet-era satellite, based on a smaller data set.

HOW DO MANUFACTURERS ARRIVE AT EFFICACY NUMBERS?

In Pfizer’s case, it waited until 94 volunteers in its late-stage clinical trial of more than 43,500 people – half got the vaccine, the other half got a placebo – tested positive after developing symptoms.

For 90%-plus efficacy, no more than eight people among those who tested positive had received the vaccine, with the rest having received the placebo.

“Roughly speaking, it’s probably around eight to 86 cases in the treated and placebo groups,” David Spiegelhalter, a Cambridge professor of risk and an expert in statistics, told Reuters.

“You don’t need a lot of fancy statistical analysis to show that this is deeply impressive. It just hits you between the eyes.”

In Russia, Sputnik V-developer Gamaleya Institute reached its preliminary 92% efficacy figure based on 20 illnesses in 16,000 volunteers as its late-stage trial progresses. It aims to reach 40,000 people.

Of the 16,000 people, about quarter got the placebo.

“It suggests that there is some effect, but it’s insufficient to estimate the magnitude of it,” Spiegelhalter said.

HOW MANY PEOPLE MUST GET SICK IN BIG VACCINE TRIALS?

Some experts say that, ideally, 150 to 160 people in a trial of tens of thousands of participants must get sick before making a reliable assessment of a vaccine’s efficacy. That’s a bit of a rule of thumb, though, open to interpretation.

“There is no such regulatory standard requiring X number of events for making a reliable decision,” the government-funded Swiss Clinical Trial Organization said. “The amount of (infections) has to be seen in relation to the disease and its risk profile. It’s rather a case-by-case evaluation.”

Typically, regulators strive to have at least 95% certainty that the trial read-out is not the result of random variations with nothing to do with the tested compound.

For trial sponsors there is safety in numbers as a large enough trial can ensure that 95% reliability hurdle is cleared. But the larger the underlying clinical benefit, the fewer trial participants needed to create that clarity.

In Pfizer and BioNTech’s trial, they planned a final analysis when 164 people had become sick, with multiple, pre-planned interim analyses along the way. They skipped an analysis at 32 patients, and once they were ready to release a look at the 62-person mark, 94 had come down sick.

Details from the Russian trial are unclear, without access to its protocol.

HOW DO THESE RESULTS STACK UP TO OTHER DRUGS, OR VACCINES FOR OTHER ILLNESSES?

In normal drug trials, for diseases like terminal cancer, benefits of new medicines may be less apparent, with survival benefits of just a few months sometimes revolutionary for patients at death’s door.

For vaccines, however, marginal protection is inadequate, and the World Health Organization ideally wants to see at least 70% efficacy in trials, while the U.S. Food and Drug Administration wants at least 50%.

The 90% efficacy reported in the Pfizer and Russian trials beats those, and appears to exceed that of typical flu vaccines, which the U.S. Centers for Disease Control and Prevention (CDC) estimate reduce the risk of sickness by 40%-60%.

For other shots, the CDC estimates the efficacy of a two-shot measles vaccine at 97%, and a two-dose chicken pox vaccine at 90%. Two doses of polio vaccine are 90% effective, rising to nearly 100% with a third.

CAN WE EXPECT EFFICACY RATES TO HOLD UP AS TRIALS ADVANCE?

Pfizer acknowledged on Monday that its final vaccine efficacy percentage may vary. Still, Spiegelhalter said the study’s design seems likely to generally hold up, based on the 94 sick participants.

“In this case, the effect is so huge, even if there is a little bit of fallback – if the effects become slightly smaller over time – that is very unlikely to be significant.”

WHAT ABOUT REAL-WORLD EFFICACY, SHOULD THE VACCINES BE APPROVED?

The interim data is promising, since it appears to demonstrate that a vaccine can be effective in preventing COVID-19.

The jump to mass vaccinations, however, presents new hurdles, in particular for an mRNA vaccine like Pfizer and BioNTech’s that must be stored and shipped at minus 70 degrees Celsius (-94°F).

Moreover, the Pfizer-BioNTech vaccine requires two doses, ideally 21 days apart. If people do not stick to the timetable, it may affect the vaccine’s efficacy.

Protection against the mumps, for instance, drops from nearly 90% to 78%, if people don’t get a follow-up shot.

Swiss epidemiologist Marcel Tanner, president of Switzerland’s Academies of Arts and Sciences and one of the government’s top COVID-19 science advisers, expects possible variations in efficacy among older people, whose immune systems wane with time, or those with immune disorders.

“Efficacy says, ‘Does it work?’ Effectiveness says, ‘Can it be applied? Can you carry the efficacy to the people?'” Tanner said. “But no question: 90% efficacy, at that stage, is a pretty good result.”

(Reporting by John Miller in Zurich, Kate Kelland in London, Ankur Banerjee in Bengaluru, Julie Steenhuysen in Chicago and Polina Ivanova in Moscow; Editing by Josephine Mason and Nick Macfie)

Alarmed by soaring COVID-19 hospitalizations, some U.S. states tighten curbs

By Sharon Bernstein and Maria Caspani

SACRAMENTO (Reuters) – Several U.S. states on Tuesday imposed restrictions to curb the spread of the coronavirus as hospitalizations soared, straining hospitals and medical resources across much of the country.

The number of patients hospitalized with COVID-19 in California has risen by 32% over the past two weeks, and intensive-care admissions have spiked by 30%, Dr. Mark Ghaly, the state’s health and human services secretary, told reporters.

As a result, Ghaly announced that three counties that are home to about 5.5 million people – San Diego, Sacramento and Stanislaus – must reverse their reopening plans and go back to the most restrictive category of regulations under which indoor dining in restaurants is not allowed and gyms and religious institutions are also not permitted to hold indoor activities.

“We anticipate if things stay they way they are … over half of California counties will have moved into a more restrictive tier” by next week, Ghaly said.

In Minnesota, Governor Tim Walz announced new restrictions as the Midwestern state reported a fresh record high in daily COVID-19 hospitalizations, and medical systems in Minnesota expressed concerns about their ability to cope with the surge.

The state reported 1,224 coronavirus hospitalizations on Tuesday, up from 1,084 the previous day and a new daily record, according to a Reuters tally.

Beginning Friday, restaurants and bars in Minnesota must close dine-in services between 10 p.m. and 4 a.m., and keep the number of patrons below 50% of capacity. The governor’s order also includes private social gatherings, which must be limited to 10 people from three households or less.

“We’ve turned our dials, we’re going to have to turn them back a little bit today,” Walz told a briefing.

In Illinois, which recorded its highest number of daily cases on Tuesday with 12,626 new infections, Governor J.B. Pritzker told reporters the majority of the state’s regions were seeing higher hospitalization rates than last spring.

Faced with rampant coronavirus infections and a strained healthcare system, Iowa Governor Kim Reynolds also took steps to curb the disease’s spread by limiting the size of social gatherings and imposing a targeted mask-wearing requirement for certain situations.

U.S. Health Secretary Alex Azar expressed concern about rising hospitalizations that were straining medical facilities in areas hardest hit by the surge, and said health officials will work to set up temporary medical facilities where they might be needed.

“As you get more cases, you get more hospitalizations,” Azar said in an interview with MSNBC. “It’s just simple math.”

There were just over 59,000 COVID-19 patients in hospitals across the United States on Monday, the country’s highest number ever of in-patients being treated for the disease. Daily new infections exceeded 100,000 for the sixth consecutive day.

Hospitalizations are a key metric of how the pandemic is progressing because, unlike case counts, they are not influenced by the number of tests performed.

The harsh statistics tallied by Reuters cemented the United States’ position as the country worst affected by the coronavirus pandemic, even as drugmaker Pfizer Inc. on Monday provided some hope: successful late-stage tests of its vaccine.

U.S. infectious disease expert Anthony Fauci welcomed the Pfizer vaccine announcement but warned the winter months promise to bring more infections as people stay indoors.

Fauci said health officials were reporting more infections from small gatherings, an indication the virus is being spread by asymptomatic people.

“There are people out there, innocently and unwittingly, who are infected, don’t have any symptoms, who are infecting others,” he told MSNBC on Tuesday. “So, much more widespread testing of asymptomatic individuals is going to be very important as we enter, and go into, these months of indoor-type gathering.”

The American Health Care Association and National Center for Assisted Living warned about a spike in COVID-19 cases in nursing homes.

“As we feared, the sheer volume of rising cases in communities across the U.S., combined with the asymptomatic and pre-symptomatic spread of this virus, has unfortunately led to an increase in new COVID cases in nursing homes,” Mark Parkinson, president and chief executive of the American Health Care Association and National Center for Assisted Living, said in a statement.

Nursing homes in the hard-hit Midwest saw a 120% increase in weekly COVID-19 cases since mid-September, the group said.

(Reporting by Doina Chiacu in Washington, Anurag Maan in Bengaluru, Sharon Bernstein in Sacramento, California; additional reporting by Maria Caspani, Peter Szekely and Gabriella Borter in New York; writing by Maria Caspani; editing by Jonathan Oatis)

Europe COVID death toll tops 300,000 as winter looms and infections surge

By Shaina Ahluwalia, Anurag Maan and Roshan Abraham

(Reuters) – More than 300,000 people have died of COVID-19 across Europe, according to a Reuters tally on Tuesday, and authorities fear that fatalities and infections will continue to rise as the region heads into winter despite hopes for a new vaccine.

With just 10% of the world’s population, Europe accounts for almost a quarter of the 1.2 million deaths globally, and even its well-equipped hospitals are feeling the strain.

After achieving a measure of control over the pandemic with broad lockdowns earlier this year, case numbers have surged since the summer and governments have ordered a second series of restrictions to limit social contacts.

In all, Europe has reported some 12.8 million cases and about 300,114 deaths. Over the past week, it has seen 280,000 cases a day, up 10% from the week earlier, representing just over half of all new infections reported globally.

Hopes have been raised by Pfizer Inc’s announcement of a potentially effective new vaccine, but it is not expected to be generally available before 2021 and health systems will have to cope with the winter months unaided.

Britain, which has imposed a fresh lockdown in England, has the highest death toll in Europe at around 49,000, and health experts have warned that with a current average of more than 20,000 cases daily, the country will exceed its “worst case” scenario of 80,000 deaths.

France, Spain, Italy and Russia have also reported hundreds of deaths a day and together, the five countries account for almost three quarters of the total fatalities.

Already facing the prospect of a wave of job losses and business failures, governments across the region have been forced to order control measures including local curfews, closing non-essential shops and restricting movement.

France, the worst-affected country in the EU, has registered more than 48,700 infections per day over the past week and the Paris region’s health authority said last week that 92% of its ICU capacity was occupied.

Facing similar pressures, Belgian and Dutch hospitals have been forced to send some severely ill patients to Germany.

In Italy, which became a global symbol of the crisis when army trucks were used to transport the dead during the early months of the pandemic, daily average new cases are at a peak at more than 32,500. Deaths have been rising by more than 320 per day over the past three weeks.

While the new vaccine being developed by Pfizer and German partner BioNTech will take time to arrive, authorities are hoping that once winter is passed, it will stem further outbreaks next year.

Citi Private Bank analysts described the news as “the first major advance toward a Post-COVID world economy”.

“More than any fiscal spending package or central bank lending program, a healthcare solution to COVID has the greatest potential to restore economic activity to its full potential…” it said in a note.

European Commission President Ursula von der Leyen on Monday said the European Union would soon sign a contract for 300 million doses of the vaccine, just hours after the drugmaker announced promising late-stage trials.

Yet health experts cautioned that the vaccine, should it be approved, was no silver bullet – not least because the genetic material it’s made from needs to be stored at temperatures of minus 70 degrees Celsius (-94 F) or below.

Such requirements pose a challenge for countries in Asia, as well as Africa and Latin America, where intense heat is often compounded by poor infrastructure.

(Reporting by Anurag Maan, Shaina Ahluwalia, Chaithra J and Roshan Abraham in Bengaluru, Sujata Rao-Coverley in London; editing by Jane Wardell, James Mackenzie, Nick Macfie and Mike Collett-White)

Fed’s Kaplan concerned about next six months as virus surges

By Ann Saphir

(Reuters) – Dallas Federal Reserve President Robert Kaplan said on Tuesday he was “cautious and concerned” about downside economic risks in the short run because of the resurgence of the coronavirus, but more optimistic in the longer term.

“The next two quarters are going to be very challenging, very difficult,” Kaplan told Bloomberg’s Future of Finance virtual conference. “Downside risks are growing with this resurgence.”

Still, he said, the U.S. economy will likely rebound strongly in the second half of next year, after a vaccine is widely available, adding that his business contacts have told him they are gearing up for exactly that.

The United States is experiencing a rise in cases, hospitalizations and deaths from COVID-19, with some state and local governments re-imposing restrictions to slow the spread.

With millions of out-of-work Americans dipping into savings built with government aid distributed earlier this year, Kaplan said, household income and spending will drop off “at some point” unless more fiscal aid is forthcoming.

Aid to small businesses in the form of a renewed Paycheck Protection Program would be particularly helpful, he said, because while financial conditions are broadly fairly loose, that is not the case for smaller businesses that rely on banks for credit.

“While we are in the teeth of the pandemic I believe we need to do what we need to do to fight the pandemic,” Kaplan said in a separate event sponsored by UT Dallas.

As long as the pandemic is ongoing, the U.S. central bank should not back away from its programs supporting economic growth, which include bond purchases totaling $120 billion a month and lending programs to corporate America, he said.

Once it subsides, he said, the U.S. will need to moderate government debt.

(Reporting by Ann Saphir; Editing by Paul Simao and Chizu Nomiyama)

One in five COVID-19 patients develop mental illness within 90 days: study

By Kate Kelland

LONDON (Reuters) – Many COVID-19 survivors are likely to be at greater risk of developing mental illness, psychiatrists said on Monday, after a large study found 20% of those infected with the coronavirus are diagnosed with a psychiatric disorder within 90 days.

Anxiety, depression and insomnia were most common among recovered COVID-19 patients in the study who developed mental health problems. The researchers from Britain’s Oxford University also found significantly higher risks of dementia, a brain impairment condition.

“People have been worried that COVID-19 survivors will be at greater risk of mental health problems, and our findings … show this to be likely,” said Paul Harrison, a professor of psychiatry at Oxford.

Doctors and scientists around the world urgently need to investigate the causes and identify new treatments for mental illness after COVID-19, Harrison said.

“(Health) services need to be ready to provide care, especially since our results are likely to be underestimates (of the number of psychiatric patients),” he added.

The study, published in The Lancet Psychiatry journal, analyzed electronic health records of 69 million people in the United States, including more than 62,000 cases of COVID-19. The findings are likely to be the same for those afflicted by COVID-19 worldwide, the researchers said

In the three months following testing positive for COVID-19, 1 in 5 survivors were recorded as having a first time diagnosis of anxiety, depression or insomnia. This was about twice as likely as for other groups of patients in the same period, the researchers said.

The study also found that people with a pre-existing mental illness were 65% more likely to be diagnosed with COVID-19 than those without.

Mental health specialists not directly involved with the study said its findings add to growing evidence that COVID-19 can affect the brain and mind, increasing the risk of a range of psychiatric illnesses.

“This is likely due to a combination of the psychological stressors associated with this particular pandemic and the physical effects of the illness,” said Michael Bloomfield, a consultant psychiatrist at University College London.

Simon Wessely, regius professor of psychiatry at King’s College London, said the finding that those with mental health disorders are also at higher risk of getting COVID-19 echoed similar findings in previous infectious disease outbreaks.

“COVID-19 affects the central nervous system, and so might directly increase subsequent disorders. But this research confirms that is not the whole story, and that this risk is increased by previous ill health,” he said.

Marjorie Wallace, chief executive of the UK mental health charity SANE, said the study echoed her charity’s experience during the pandemic.

“Our helpline is dealing with an increasing number of first-time callers who are being triggered into mental health problems, as well as those who are relapsing because their fear and anxiety have become intolerable,” she said.

(Reporting by Kate Kelland; Editing by Bill Berkrot and Angus MacSwan)